Stock NXL NEXALIN TECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
1.39 USD -4.14% Intraday chart for Nexalin Technology, Inc. -0.71% +243.38%
Jul. 01 Nexalin Technology Completes $5.3 Million Share Offering MT
Jun. 28 Top Midday Decliners MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Effect of add-on transcranial alternating current stimulation (tACS) in major depressive disorder: A randomized controlled trial
PU
Nexalin Technology Completes $5.3 Million Share Offering
MT
Nexalin Technology Announces Closing of $5.2 Million Public Offering
GL
Top Midday Decliners
MT
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation
MT
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell
MT
Top Premarket Decliners
MT
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
GL
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
AQ
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
CI
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
GL
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 MA Neurostimulation Device by the Brazilian Health Regulatory Agency
CI
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
GL
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
GL
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
GL
Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device
CI
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
GL
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
GL
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NXL Stock
  4. News Nexalin Technology, Inc.